April 23rd, 2021 | 07:32 CEST
Evonik, SKRR Exploration, AMS - Protect your money!
Table of contents:
"[...] We have a clear strategy for neutralizing sovereign risk in Papua New Guinea. [...]" Matthew Salthouse, CEO, Kainantu Resources
Protection against crises and inflation
Everyone should now be aware that the world has not become safer after Donald Trump was voted out of office. On the contrary, tensions between the US and China and Russia have, if anything, become even more intense since the Biden administration. For this alone, an investment in gold as a crisis currency and "safe haven" would be worthwhile. However, the precious yellow metal should instead serve as capital and inflation protection. The warning signs for an uncontrollable upward price spiral are too dangerous. Historic debts of the Western industrialized countries, falling yields on US government bonds and rampant economic stimulus programs should already currently push the gold price into significantly higher realms.
"Still" in correction mode
If you look at the current chart of the gold price, you can see a brightening, but from a bullish sentiment, it is still far away. Since August, the price has corrected from over USD 2,060 to USD 1,680 in March. Twice, this critical support was successfully tested. Currently, the price is quoted at USD 1,787. An important step for further positive development would be a breakout of the upward trend formed since August at around USD 1,810. On the downside, the gold price should not leave the support line at USD 1,680; otherwise, this would likely result in a more significant, accelerated sell-off. We see strongly rising prices and new all-time highs based on the fundamental data in the long term.
Fundamentally, gold mining stocks are once again extremely attractive after the correction that has taken place. In addition to the heavyweights such as Barrick Gold or Newmont, there are interesting entry opportunities in smaller explorers.
A team of mining industry veterans has joined forces to build the next big thing. That is what happened with gold explorer SKRR Exploration. Under the leadership of CEO Sherman Dahl, a shell company was acquired last year and, as things stand, five world-class deposits were brought in. These are located in Saskatchewan, one of the world's most renowned mining areas, specifically in the Trans-Hudson corridor. SKRR believes that the Trans-Hudson Corridor is geologically similar to the Abitibi Gold Belt. The Abitibi Gold Belt, which straddles the Ontario-Quebec border, has historically produced approximately 200 million ounces of gold.
Drillers are running
Currently, the most significant project is Irving/Leland, which covers an area of more than 23,500 hectares and is less than 10 km from rival SSR Mining's producing Seabee Gold Mine. The program is planned for the whole year, so we expect the news flow to be continuous. By the end of 2022, the aim is to have determined a resource, giving the projects a definable commercial value. By then, at the latest, the majors, who are currently swimming in money, should take notice of SKRR Exploration. However, the management network is likely to get wind of the success story sooner. At the beginning of April, another small capital increase was carried out at CAD 0.27. The share, which investors can purchase in Toronto and Frankfurt, is quoted at CAD 0.18. A long-term success story could develop here.
Free from inflation
Companies in the healthcare sector suffer less from inflation fears, as price increases are typically passed on to the end consumer. In addition, the price currently plays a subordinate role in the fight against the Coronavirus, as in the case of Evonik. The specialty chemicals company has been working with the pharmaceutical industry for many years. In addition to production, the MDAX-listed group develops combinations of excipients and active ingredients, known as formulations. For BioNTech's vaccine, the Essen-based company is responsible for producing the lipids, along with Merck, the Darmstadt-based pharmaceutical and specialty chemicals group. Evonik produces two different lipids that, together with other such lipid-like molecules, enclose the messenger substance of the mRNA vaccine "Comirnaty" in a nanoshell. Only this makes it possible to release the active ingredient from BioNTech at the right place in the body, enabling the vaccine to take effect.
Evonik has now announced that it has made faster progress than planned to expand lipid production for BioNTech's Corona vaccine. The facilities at the Hanau site have been set up and the first lipids are being delivered. Initially, the production of larger quantities had only been announced for the second half of the year. After doubling its share price since March 2020, Evonik is currently struggling with the broad resistance line around EUR 31. However, after the performance of the last few weeks, a consolidation to the area around EUR 28 is likely to take place first.
Is the apple falling from the tree?
Things do not look good if you look at the chart of the Austrian provider of high-performance sensor solutions, AMS AG. At the beginning of 2018, it was still at CHF 80; currently, the share price is falling like a stone and is quoted at CHF 16. The reasons are obvious but have not yet been commented on by the Company. The technology giant Apple is said to no longer prefer AMS sensors in the future and has already started to install sensors from AMS competitors. Our advice: Hands off!
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.